Update on share buyback extension

In its FY24 Preliminary Results to 31 December 2024 published on 25 March 2025, Fever-Tree announced a £29 million extension (the "Extension") of the Company's share buyback programme announced on 17 February 2025 (the "Programme"), taking the total programme maximum consideration to £100 million. The Company today announces the commencement the Extension which is to be conducted until 31 December 2025 to buyback ordinary shares of a nominal value of 0.25 pence each (the "Shares").

Fever-Tree has amended its agreement with Investec Bank plc ("Investec") pursuant to which Investec will continue to carry out on-market purchases of Shares on its behalf and to make trading decisions independently of the Company. Save as set out herein, the Programme will otherwise continue to be subject to the same parameters set out in the Company's announcement of 17 February 2025.

Any purchase of Shares under the Programme moving forwards will be executed in accordance with certain pre-set parameters and in accordance with the Company's existing general authority to repurchase Shares granted by its shareholders at the annual general meeting held on 6 June 2024 and any subsequent general authorities granted by the Company's shareholders, the Market Abuse Regulation (596/2014) as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and UKLR 9.6.2 using the average daily volume of Ordinary Shares traded in March 2025, being the month preceding the month of this announcement. The Company may repurchase up to 25% of this average daily volume per day during the programme.